What is AlloVir, Inc. (ALVR)?

AlloVir, Inc. (ALVR) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ALVR?

The current price of ALVR is $9.81. Prices are updated in real time on Stocks360.

What is ALVR's price-to-earnings (PE) ratio?

ALVR's trailing twelve-month PE ratio is -5.74, based on current price and earnings per share data available on Stocks360.

What is ALVR's market capitalization?

ALVR's market capitalization is $49,475,362.00, placing it in the small-cap tier.

AlloVir, Inc. (ALVR)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$9.81

Market Cap

$49.48M

PE (TTM)

-5.74

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.62

Day Range

$9.55 – $10.32

52-wk Range

$7.96 – $24.15

Avg Volume

N/A

Volume

9.40K

AlloVir, Inc. (ALVR) is a publicly traded company in the Healthcare sector. Latest price: $9.81. Market cap $49.48M. Trailing PE -5.74. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 17, 2026

EPS $-0.92 vs est. $-4.37

Beat by $3.45

Proprietary Signals

Signal snapshot temporarily unavailable.

About AlloVir, Inc.

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-5.74×
P/S (TTM)	0.00×
P/B	4.05×
P/FCF (TTM)	-1.20×
EV / EBITDA	-0.34×
EV / Sales	0.00×
Earnings Yield	-23.33%
Free Cash Flow Yield	-83.31%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$7.70M
Net Income (TTM)	-$11.54M
Free Cash Flow (TTM)	-$44.10M
Net Debt	-$41.77M
Working Capital	$87.18M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-88.23%
Return on Invested Capital	-52.40%